Parallel Advisors’s Psyence Biomedical Warrant PBMWW Stock Holding History

Parallel Advisors’s Portfolio PBMWW Stock Details PBMWW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$668	Hold	27,500	–	–	﹤0.01%	3753
2026 Q1	$500	Hold	27,500	–	–	﹤0.01%	3673
2025 Q4	$510	Hold	27,500	–	–	﹤0.01%	3400
2025 Q3	$693	Sell	27,500 -22,500	-45%	-$567	﹤0.01%	3289
2025 Q2	$1.01K	Buy	+50,000	New	+$800	﹤0.01%	3188

Other funds holding PBMWW

HCI

Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Parallel Advisors's PBMWW Position: Q2 2026 in Review

Parallel Advisors held its Psyence Biomedical Warrant (PBMWW) position steady in Q2 2026 at 27,500 shares worth $668. The position accounts for ﹤0.01% of the portfolio, ranked #3753.

Parallel Advisors first reported a position in PBMWW in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.01K in Q2 2025. 18 funds tracked by Wall St. Rank hold PBMWW as of Q2 2026.

Parallel Advisors held 27,500 shares of Psyence Biomedical Warrant worth $668 as of Q2 2026.
Parallel Advisors left its Psyence Biomedical Warrant share count unchanged in Q2 2026.
Psyence Biomedical Warrant made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3753 holding.
Parallel Advisors first reported a position in Psyence Biomedical Warrant in Q2 2025 and has held it in 5 quarters since.
Parallel Advisors's Psyence Biomedical Warrant position peaked at $1.01K in Q2 2025.
18 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.